Scientists Find a New Way to Outsmart Cancer's Hidden Defense System

Scientists at MIT and Stanford have developed a groundbreaking approach that removes cancer's protective sugar coating, allowing the immune system to recognize and destroy tumor cells with unprecedented effectiveness. Their innovative hybrid molecules, called AbLecs, combine antibodies with sugar-blocking proteins to overcome one of cancer's most clever defense mechanisms.

How Does Cancer Hide from Our Immune System?

Cancer cells are remarkably sneaky. They coat themselves with special sugar molecules called glycans that act like an invisibility cloak, preventing immune cells from recognizing them as threats. These sugars, particularly one called sialic acid, bind to receptors on immune cells and essentially tell them to "stand down" rather than attack.

"When Siglecs on immune cells bind to sialic acids on cancer cells, it puts the brakes on the immune response. It prevents that immune cell from becoming activated to attack and destroy the cancer cell, just like what happens when PD-1 binds to PD-L1," explains Jessica Stark, the Underwood-Prescott Career Development Professor at MIT who led the research.

What Makes This New Treatment Different?

The MIT team solved a longstanding problem in cancer treatment by creating molecules that work like guided missiles. The AbLec molecules use an antibody portion to home in on cancer cells, then deploy a lectin component that blocks the sugar camouflage once it arrives at the tumor site.

Previous attempts to block these sugar interactions failed because the blocking proteins weren't strong enough on their own. But by hitching them to antibodies that specifically target cancer cells, the researchers achieved much higher concentrations where they're needed most. The approach showed several key advantages:

• Targeted Delivery: The antibody portion ensures the treatment goes directly to cancer cells rather than affecting healthy tissue
• Enhanced Immune Response: Blocking the sugar shield allows natural killer cells and macrophages to attack tumors more aggressively
• Flexible Design: Researchers can swap different antibodies and lectins to target various cancer types and immune pathways
• Superior Performance: In laboratory tests, AbLecs outperformed current antibody therapies alone

What Did the Research Show?

The team tested their approach using trastuzumab, an existing breast cancer drug, combined with lectins that target specific sugar molecules. In laboratory experiments with cultured cells, the AbLec molecules successfully changed how immune cells behaved, pushing them to attack and kill cancer cells more effectively.

When tested in specially engineered mice that express human immune receptors, treatment with AbLecs led to fewer lung metastases compared to treatment with the antibody alone. The researchers also demonstrated the system's versatility by successfully swapping in different cancer-targeting antibodies like rituximab and cetuximab.

"AbLecs are really plug-and-play. They're modular," Stark notes. "You can imagine swapping out different decoy receptor domains to target different members of the lectin receptor family, and you can also swap out the antibody arm. This is important because different cancer types express different antigens, which you can address by changing the antibody target."

The research addresses a critical gap in cancer treatment. While current checkpoint inhibitors that target the PD-1/PD-L1 pathway help some patients achieve long-lasting remission, many others see little to no benefit. This sugar-blocking approach represents an entirely different way to remove the brakes on immune responses against cancer.

Stark, Bertozzi, and their colleagues have launched Valora Therapeutics to develop lead AbLec candidates for clinical testing. They aim to begin human trials within the next two to three years, potentially offering new hope for cancer patients who don't respond to current immunotherapies.